Eli Lilly and (LLY) 10-K2011 Q4 Annual report

Filed: 24 Feb 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: AAi, adolescent, agonist, alfa, analgesic, anticompetitive, Appendix, appraisal, Arxxant, attack, Ballard, Baxter, biennial, bioscience, Bookand, breakdown, Bristol, cap, capability, certiorari, ChemGen, Chugai, communicated, concurrently, Crowe, Darvon, deadline, derecognition, drotrecogin, drove, Dulaglutide, Edivoxetine, egg, empagliflozin, Enzastaurin, estate, factual, Fionnuala, formula, fragility, futility, Genzyme, glargine, glucose, glutamate, Greece, heartworm, Hrvatska, indemnified, infrastructure, ingested, intestinal, intrusion, ixekizumab, Janssen, Jentadueto, Likewise, liver, MAb, Maria, meat, mediation, metabotropic, methionil, mGlu, modest, mortality, newer, NME, NV, onThe, opt, opted, parasite, payer, PCT, penalizing, petition, Pharmaceuticia, pharmacological, Pliva, pomaglumetad, PPACA, Prasco, prominence, propoxyphene, protocol, Racketeer, random, randomized, rata, reacquired, recession, rehearing, reliant, ReliOn, retinopathy, septic, shock, sluggish, sodium, sophisticated, spurred, summer, Supplementary, taxpayer, Tradjenta, Trajenta, Trazenta, Treaty, underarm, vulnerable, Walsh, Xanodyne

Removed: adjunctive, Advancement, advancing, air, amortizing, annualized, antiplatelet, appellate, assigned, authoritative, autism, bench, biopharmaceutical, bound, brand, calculation, causal, challenger, childhood, close, closed, Cobalt, Colored, Columbia, combined, complaint, conclusion, conditionally, consent, consolidate, constructing, contesting, Covance, cow, created, credible, defeating, deficit, dementia, deny, directed, discontinued, EDPA, Efient, elderly, entity, entry, exit, facing, fasttm, feature, fight, financed, forma, Fraud, German, Greenfield, grow, guided, halted, harmed, HHS, holder, Idaho, impacted, Impax, improvement, inclusion, indexed, Injury, inquiry, integrate, invalidity, inventor, Iowa, judicial, justified, kinase, Lupin, medically, Michigan, mild, Minnesota, misdemeanor, Mississippi, Monsanto, Montana, moved, multistate, NAACP, neurological, nonaudit, nonexistent, notified, Novopharm, offered, OIG, oncolytic, outlicensing, overpaid, owe, participate, Paul, pertaining, plaintiff, pled, presently, preservative, prosecuted, racial, reimburse, reject, rendered, replaced, representative, secondary, separate, separately, settling, SGX, Sixteen, South, spanning, stayed, Steven, strongly, sued, suspended, tentative, teplizumab, thimerosal, Transnational, TransPharma, unenforceable, unfiled, unsatisfied, upgrade, Utah, vaccine, Vanderbilt, violated, Virginia, vote, weekly, Welch, withdraw, withdrew, Wockhardt, write

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

LLY similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32 Section 1350 Certification

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Eli Lilly and Company, an Indiana corporation (the “Company”), does hereby certify that, to the best of his knowledge:

The Annual Report on Form 10-K for the year ended December 31, 2011 (the “Form 10-K”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: February 24, 2012				/s/ John C. Lechleiter
				John C. Lechleiter, Ph.D.
				Chairman of the Board, President, and Chief Executive Officer



Date: February 24, 2012				/s/ Derica W. Rice
				Derica W. Rice
				Executive Vice President, Global Services and Chief Financial Officer